HER2-Positive Colorectal Cancer: Novel Approaches : Episode 7

Real-World Use of HER2-Directed Therapies in Colorectal Cancers

April 28, 2023

Tanios S. Bekaii-Saab, MD, Mayo Clinic
Cathy Eng, MD, Vanderbilt University

Video

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

EP: 1.Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes

EP: 2.Colorectal Cancer: An Overview on Molecular Profiling

EP: 3.Role of HER2 Expression in Colorectal Cancer

EP: 4.Role of Circulating Tumor DNA Testing in Colorectal Cancer

EP: 5.Treatment Algorithm for Metastatic Colorectal Cancer

EP: 6.HER2-Amplified Colorectal Cancer: Clinical Trial Data

EP: 7.Real-World Use of HER2-Directed Therapies in Colorectal Cancers

EP: 8.Evolutions in the HER2-Amplified CRC Treatment Landscape

EP: 9.Audience Q&A: Best Practices in Managing HER2-Amplified CRC

Related Videos

Scott T. Tagawa, MD, MS, FACP, FASCO

Video 16 - "Trajectory of Evolving HCC Treatment Landscape"

Video 15 - "REGONEXT Study: Driving Second-line HCC Treatment Strategy"

A panel of 4 experts on colorectal cancer

A panel of 4 experts on colorectal cancer

Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center

A panel of 5 experts on renal cell carcinoma

Chandler H. Park, MD, an expert on renal cell carcinoma

Related Content

Steven O’Day, MD

Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC

April 12th 2024

Carrie L. Kitko, MD, associate professor, pediatrics, medical director, the Pediatric Stem Cell Transplantation Program, the Ingram Professor of Pediatric Oncology, Monroe Carell Jr. Children’s Hospital at Vanderbilt; Sagar S. Patel, MD, director, Communications and Media Relationships, the Division of Hematology, the University of Utah Huntsman Cancer Institute

Kitko and Patel Emphasize the Importance of GVHD Research and Awareness

February 19th 2024

Eric Scott Christenson, MD

Copanlisib Plus Nivolumab Demonstrates Activity in Microsatellite Stable Colorectal Cancer

Seth Wander, MD, PhD; Paolo Tarantino, MD; Daniel P. Petrylak, MD; Lionel A. Kankeu Fonkoua, MD; Solange Peters, MD, PhD; Edgardo Santos, MD, FACP, FCCP

Expert Insights on the United States Chemotherapy Shortage

October 9th 2023

3D rendered Medical Illustration of Male Anatomy - Colon Cancer; Descending Colon. | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Phase 2 Data Support Use of RNX-051 in Cancerous and Precancerous CRC

J. Randolph Hecht, MD, of UCLA

Preliminary Data Hint at PFS Benefit With Personalized Neoantigen Vaccine in Metastatic MSS CRC

Related Content

Steven O’Day, MD

Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC

April 12th 2024

Carrie L. Kitko, MD, associate professor, pediatrics, medical director, the Pediatric Stem Cell Transplantation Program, the Ingram Professor of Pediatric Oncology, Monroe Carell Jr. Children’s Hospital at Vanderbilt; Sagar S. Patel, MD, director, Communications and Media Relationships, the Division of Hematology, the University of Utah Huntsman Cancer Institute

Kitko and Patel Emphasize the Importance of GVHD Research and Awareness

February 19th 2024

Eric Scott Christenson, MD

Copanlisib Plus Nivolumab Demonstrates Activity in Microsatellite Stable Colorectal Cancer

Seth Wander, MD, PhD; Paolo Tarantino, MD; Daniel P. Petrylak, MD; Lionel A. Kankeu Fonkoua, MD; Solange Peters, MD, PhD; Edgardo Santos, MD, FACP, FCCP

Expert Insights on the United States Chemotherapy Shortage

October 9th 2023

3D rendered Medical Illustration of Male Anatomy - Colon Cancer; Descending Colon. | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Phase 2 Data Support Use of RNX-051 in Cancerous and Precancerous CRC

J. Randolph Hecht, MD, of UCLA

Preliminary Data Hint at PFS Benefit With Personalized Neoantigen Vaccine in Metastatic MSS CRC

Latest Conference Coverage

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.